{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:32:58Z","timestamp":1786368778130,"version":"build-2736575974"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"DOI":"10.1007\/s11897-026-00774-9","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:45:18Z","timestamp":1786322718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Urinary Biomarkers for the Risk Assessment and Management of Heart Failure: Pearls and Pitfalls"],"prefix":"10.1007","volume":"23","author":[{"given":"Bethany","family":"Roehm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Vaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"774_CR1","doi-asserted-by":"publisher","unstructured":"Forman DE et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure, J Am Coll Cardiol, vol. 43, no. 1, pp. 61\u2009\u2013\u20097, Jan 7 2004, https:\/\/doi.org\/10.1016\/j.jacc.2003.07.031","DOI":"10.1016\/j.jacc.2003.07.031"},{"key":"774_CR2","doi-asserted-by":"publisher","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. Feb 2014;35(7):455\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/eht386.","DOI":"10.1093\/eurheartj\/eht386"},{"key":"774_CR3","doi-asserted-by":"publisher","unstructured":"Chen JJ, et al. Acute Kidney Disease After Acute Decompensated Heart Failure. Kidney Int Rep. Mar 2022;7(3):526\u201336. https:\/\/doi.org\/10.1016\/j.ekir.2021.12.033.","DOI":"10.1016\/j.ekir.2021.12.033"},{"key":"774_CR4","doi-asserted-by":"publisher","unstructured":"Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury, Kidney Int, vol. 62, no. 1, pp. 237\u2009\u2013\u200944, Jul 2002, https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00433.x","DOI":"10.1046\/j.1523-1755.2002.00433.x"},{"key":"774_CR5","doi-asserted-by":"publisher","unstructured":"Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int. 2006;69(3):440\u20139. https:\/\/doi.org\/10.1038\/sj.ki.5000141.","DOI":"10.1038\/sj.ki.5000141"},{"issue":"5","key":"774_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00125-008-0961-8","volume":"51","author":"SC Satchell","year":"2008","unstructured":"Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008;51(5):714\u201325. https:\/\/doi.org\/10.1007\/s00125-008-0961-8.","journal-title":"Diabetologia"},{"issue":"1","key":"774_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.xkme.2020.10.005","volume":"3","author":"CL Gil","year":"2021","unstructured":"Gil CL, Hooker E, Larrivee B. Diabetic kidney disease, endothelial damage, and podocyte-endothelial crosstalk. Kidney Med. 2021;3(1):105\u201315. https:\/\/doi.org\/10.1016\/j.xkme.2020.10.005.","journal-title":"Kidney Med"},{"issue":"4S","key":"774_CR8","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"C. K. D. W. G. Kidney Disease: Improving Global Outcomes","year":"2024","unstructured":"C. K. D. W. G. Kidney Disease: Improving Global Outcomes. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"key":"774_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijcard.2016.07.135","volume":"222","author":"T Bekfani","year":"2016","unstructured":"Bekfani T, et al. Sarcopenia in patients with heart failure with preserved ejection fraction: impact on muscle strength, exercise capacity and quality of life. Int J Cardiol. 2016;222:41\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2016.07.135.","journal-title":"Int J Cardiol"},{"issue":"11","key":"774_CR10","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/ejhf.1304","volume":"20","author":"A Emami","year":"2018","unstructured":"Emami A, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF), (in eng). Eur J Heart Fail. 2018;20(11):1580\u20137. 2018\/11\/\/undefined.","journal-title":"Eur J Heart Fail"},{"key":"774_CR11","unstructured":"Disease GK. Improving Global Outcomes Acute Kidney Injury Work, KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl, 2, pp. 1\u2013138, 2012."},{"key":"774_CR12","doi-asserted-by":"publisher","unstructured":"Gerstein HC et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals, JAMA, vol. 286, no. 4, pp. 421-6, Jul 25 2001, https:\/\/doi.org\/10.1001\/jama.286.4.421","DOI":"10.1001\/jama.286.4.421"},{"issue":"1","key":"774_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.ajkd.2011.02.391","volume":"58","author":"S Blecker","year":"2011","unstructured":"Blecker S, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011;58(1):47\u201355. https:\/\/doi.org\/10.1053\/j.ajkd.2011.02.391.","journal-title":"Am J Kidney Dis"},{"key":"774_CR14","doi-asserted-by":"publisher","unstructured":"Capes SE, Gerstein HC, Negassa A, Yusuf S. Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction, Diabetes Care, vol. 23, no. 3, pp. 377\u2009\u2013\u200980, Mar 2000, https:\/\/doi.org\/10.2337\/diacare.23.3.377","DOI":"10.2337\/diacare.23.3.377"},{"key":"774_CR15","doi-asserted-by":"publisher","unstructured":"Jackson CE et al. Albuminuria in chronic heart failure: prevalence and prognostic importance, Lancet, vol. 374, no. 9689, pp. 543\u2009\u2013\u200950, Aug 15 2009. https:\/\/doi.org\/10.1016\/S0140-6736(09)61378-7","DOI":"10.1016\/S0140-6736(09)61378-7"},{"issue":"4","key":"774_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cjca.2019.09.001","volume":"36","author":"M Shuvy","year":"2020","unstructured":"Shuvy M, Zwas DR, Lotan C, Keren A, Gotsman I. Albuminuria: associated with heart failure severity and impaired clinical outcomes. Can J Cardiol. 2020;36(4):527\u201334. https:\/\/doi.org\/10.1016\/j.cjca.2019.09.001.","journal-title":"Can J Cardiol"},{"key":"774_CR17","doi-asserted-by":"publisher","unstructured":"Masson S, et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial. Circ Heart Fail. Jan 2010;3(1):65\u201372. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.881805.","DOI":"10.1161\/CIRCHEARTFAILURE.109.881805"},{"issue":"4","key":"774_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/eurjhf\/hfs001","volume":"14","author":"M Miura","year":"2012","unstructured":"Miura M, et al. Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study. Eur J Heart Fail. 2012;14(4):367\u201376. https:\/\/doi.org\/10.1093\/eurjhf\/hfs001.","journal-title":"Eur J Heart Fail"},{"key":"774_CR19","doi-asserted-by":"publisher","unstructured":"Takaoka Y, Horiuchi Y, Strader M, Murray P, Wettersten N. Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure. ESC Heart Fail. Dec 2025;12(6):4369\u201378. https:\/\/doi.org\/10.1002\/ehf2.70006.","DOI":"10.1002\/ehf2.70006"},{"issue":"1","key":"774_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000536222","volume":"14","author":"P Llacer","year":"2024","unstructured":"Llacer P, et al. Trajectory of Urine Albumin-Creatinine Ratio in Patients with Acute Heart Failure. Cardiorenal Med. 2024;14(1):74\u201380. https:\/\/doi.org\/10.1159\/000536222.","journal-title":"Cardiorenal Med"},{"issue":"7","key":"774_CR21","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s00380-022-02025-y","volume":"37","author":"Y Matsumoto","year":"2022","unstructured":"Matsumoto Y, et al. Urine albumin-to-creatinine ratio on admission predicts early rehospitalization in patients with acute decompensated heart failure. Heart Vessels. 2022;37(7):1184\u201394. https:\/\/doi.org\/10.1007\/s00380-022-02025-y.","journal-title":"Heart Vessels"},{"key":"774_CR22","doi-asserted-by":"publisher","unstructured":"Wang Y, et al. Elevated urinary albumin concentration predicts worse clinical outcomes in hospitalized acute decompensated heart failure patients. ESC Heart Fail. Aug 2021;8(4):3037\u201348. https:\/\/doi.org\/10.1002\/ehf2.13399.","DOI":"10.1002\/ehf2.13399"},{"key":"774_CR23","doi-asserted-by":"crossref","unstructured":"Randomised placebo-controlled trial. of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), Lancet, vol. 349, no. 9069, pp. 1857-63, Jun 28 1997. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9217756","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"774_CR24","doi-asserted-by":"publisher","unstructured":"Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. Jul 11 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","DOI":"10.1056\/NEJMoa2403347"},{"key":"774_CR25","doi-asserted-by":"publisher","unstructured":"Bakris GL et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med, 383, 23, pp. 2219\u201329, Dec 3 2020, https:\/\/doi.org\/10.1056\/NEJMoa2025845","DOI":"10.1056\/NEJMoa2025845"},{"key":"774_CR26","doi-asserted-by":"publisher","unstructured":"Selvaraj S, et al. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. Nov 2018;11(11):e005288. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005288.","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288"},{"key":"774_CR27","doi-asserted-by":"publisher","unstructured":"The E-KCG et al. Empagliflozin in Patients with Chronic Kidney Disease, N Engl J Med, vol. 388, no. 2, pp. 117\u2013127, Jan 12 2023, https:\/\/doi.org\/10.1056\/NEJMoa2204233","DOI":"10.1056\/NEJMoa2204233"},{"key":"774_CR28","doi-asserted-by":"publisher","unstructured":"Damman K, et al. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. Jun 2018;6(6):489\u201398. https:\/\/doi.org\/10.1016\/j.jchf.2018.02.004.","DOI":"10.1016\/j.jchf.2018.02.004"},{"key":"774_CR29","doi-asserted-by":"publisher","unstructured":"Curthoys NP, Moe OW. Proximal tubule function and response to acidosis, Clin J Am Soc Nephrol, vol. 9, no. 9, pp. 1627-38, Sep 5 2014, https:\/\/doi.org\/10.2215\/CJN.10391012","DOI":"10.2215\/CJN.10391012"},{"key":"774_CR30","doi-asserted-by":"publisher","unstructured":"Palmer LG, Schnermann J. Integrated control of Na transport along the nephron. Clin J Am Soc Nephrol, 10, 4, pp. 676\u2009\u2013\u200987, Apr 7 2015, https:\/\/doi.org\/10.2215\/CJN.12391213","DOI":"10.2215\/CJN.12391213"},{"key":"774_CR31","doi-asserted-by":"publisher","unstructured":"Van den Eynde J, Verbrugge FH. Water and electrolyte homeostasis during decongestion in heart failure. Eur J Heart Fail. Dec 2025;27(12):3072\u201383. https:\/\/doi.org\/10.1002\/ejhf.3727.","DOI":"10.1002\/ejhf.3727"},{"key":"774_CR32","doi-asserted-by":"publisher","unstructured":"Ferreira JP, et al. Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clin Res Cardiol. Jun 2016;105(6):489\u2013507. https:\/\/doi.org\/10.1007\/s00392-015-0945-x.","DOI":"10.1007\/s00392-015-0945-x"},{"key":"774_CR33","doi-asserted-by":"publisher","unstructured":"Luk A, et al. First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization. Am Heart J. Sep 2018;203:95\u2013100. https:\/\/doi.org\/10.1016\/j.ahj.2018.01.013.","DOI":"10.1016\/j.ahj.2018.01.013"},{"key":"774_CR34","doi-asserted-by":"publisher","unstructured":"Cunningham JW, et al. Lower urine sodium predicts longer length of stay in acute heart failure patients: Insights from the ROSE AHF trial. Clin Cardiol. Jan 2020;43(1):43\u20139. https:\/\/doi.org\/10.1002\/clc.23286.","DOI":"10.1002\/clc.23286"},{"key":"774_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijcard.2017.08.053","volume":"254","author":"S Honda","year":"2018","unstructured":"Honda S, et al. Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure. Int J Cardiol. 2018;254:189\u201394. https:\/\/doi.org\/10.1016\/j.ijcard.2017.08.053.","journal-title":"Int J Cardiol"},{"issue":"6","key":"774_CR36","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cardfail.2014.03.006","volume":"20","author":"D Singh","year":"2014","unstructured":"Singh D, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail. 2014;20(6):392\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2014.03.006.","journal-title":"J Card Fail"},{"key":"774_CR37","doi-asserted-by":"publisher","unstructured":"Testani JM, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure, (in eng). Circ Heart Fail. 2016;9(1). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002370. e002370, 2016\/01\/\/undefined.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002370"},{"key":"774_CR38","doi-asserted-by":"publisher","unstructured":"Ter Maaten JM, et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat Med. Oct 2023;29(10):2625\u201332. https:\/\/doi.org\/10.1038\/s41591-023-02532-z.","DOI":"10.1038\/s41591-023-02532-z"},{"key":"774_CR39","doi-asserted-by":"publisher","unstructured":"Dauw J et al. Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study, Circ Heart Fail, vol. 17, no. 1, p. e011105, Jan 2024, https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.011105","DOI":"10.1161\/CIRCHEARTFAILURE.123.011105"},{"key":"774_CR40","doi-asserted-by":"publisher","unstructured":"Damman K, et al. Renal function and natriuresis-guided diuretic therapy - a pre-specified analysis from the PUSH-AHF trial. Eur J Heart Fail. Jun 2024;26(6):1347\u201357. https:\/\/doi.org\/10.1002\/ejhf.3228.","DOI":"10.1002\/ejhf.3228"},{"key":"774_CR41","doi-asserted-by":"publisher","unstructured":"Armanini D, et al. Evaluation and implications of salt intake and excretion. J Clin Hypertens (Greenwich). Jul 2019;21(7):950\u20132. https:\/\/doi.org\/10.1111\/jch.13589.","DOI":"10.1111\/jch.13589"},{"key":"774_CR42","doi-asserted-by":"publisher","unstructured":"Weiner ID, Mitch WE, Sands JM. Urea and Ammonia Metabolism and the Control of Renal Nitrogen Excretion. Clin J Am Soc Nephrol. Aug 7 2015;10(8):1444\u201358. https:\/\/doi.org\/10.2215\/CJN.10311013.","DOI":"10.2215\/CJN.10311013"},{"key":"774_CR43","doi-asserted-by":"publisher","unstructured":"Goldsmith SR, Francis GS, Cowley AW Jr., Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. Jun 1983;1(6):1385\u201390. https:\/\/doi.org\/10.1016\/s0735-1097(83)80040-0.","DOI":"10.1016\/s0735-1097(83)80040-0"},{"key":"774_CR44","doi-asserted-by":"publisher","unstructured":"Nogi K et al. Prognostic Value of Fractional Excretion of Urea Nitrogen at Discharge in Acute Decompensated Heart Failure, J Am Heart Assoc, vol. 10, no. 16, p. e020480, Aug 17 2021, https:\/\/doi.org\/10.1161\/JAHA.120.020480","DOI":"10.1161\/JAHA.120.020480"},{"key":"774_CR45","doi-asserted-by":"publisher","unstructured":"Watanabe Y, et al. Utility of fractional excretion of urea nitrogen in heart failure patients with chronic kidney disease. ESC Heart Fail. Jun 2023;10(3):1706\u201316. https:\/\/doi.org\/10.1002\/ehf2.14327.","DOI":"10.1002\/ehf2.14327"},{"issue":"5","key":"774_CR46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.cardfail.2020.01.019","volume":"26","author":"ZL Cox","year":"2020","unstructured":"Cox ZL, et al. Effect of loop diuretics on the fractional excretion of urea in decompensated heart failure. J Card Fail. 2020;26(5):402\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2020.01.019.","journal-title":"J Card Fail"},{"issue":"1\u20132","key":"774_CR47","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/s0167-4838(00)00152-7","volume":"1482","author":"L Kjeldsen","year":"2000","unstructured":"Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta. 2000;1482(1\u20132):272\u201383. https:\/\/doi.org\/10.1016\/s0167-4838(00)00152-7.","journal-title":"Biochim Biophys Acta"},{"key":"774_CR48","doi-asserted-by":"publisher","unstructured":"Romejko K, Markowska M, Niemczyk S. The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL). Int J Mol Sci. Jun 21 2023;24(13). https:\/\/doi.org\/10.3390\/ijms241310470.","DOI":"10.3390\/ijms241310470"},{"key":"774_CR49","doi-asserted-by":"crossref","unstructured":"Mishra J et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury, (in eng), Journal of the American Society of Nephrology: JASN, vol. 14, no. 10, pp. 2534\u20132543. 2003\/10\/\/undefined 2003, doi: 10.1097\/01.asn.0000088027.54400.c6.","DOI":"10.1097\/01.ASN.0000088027.54400.C6"},{"key":"774_CR50","doi-asserted-by":"publisher","unstructured":"Mishra J et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery, (in eng), Lancet, vol. 365, no. 9466, pp. 1231\u20131238, 2005\/04\/02\/8 2005. https:\/\/doi.org\/10.1016\/S0140-6736(05)74811-X","DOI":"10.1016\/S0140-6736(05)74811-X"},{"key":"774_CR51","doi-asserted-by":"publisher","unstructured":"Collins SP, et al. Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail. Sep 2012;14(9):1020\u20139. https:\/\/doi.org\/10.1093\/eurjhf\/hfs087.","DOI":"10.1093\/eurjhf\/hfs087"},{"key":"774_CR52","doi-asserted-by":"publisher","unstructured":"Murray PT, et al. Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). J Card Fail. Aug 2019;25(8):654\u201365. https:\/\/doi.org\/10.1016\/j.cardfail.2019.05.009.","DOI":"10.1016\/j.cardfail.2019.05.009"},{"issue":"2","key":"774_CR53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ejhf.1642","volume":"22","author":"N Wettersten","year":"2020","unstructured":"Wettersten N, et al. Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study, (in eng). Eur J Heart Fail. 2020;22(2):251\u201363. 2020\/02\/\/undefined.","journal-title":"Eur J Heart Fail"},{"key":"774_CR54","doi-asserted-by":"publisher","unstructured":"Zhou LZ, et al. Development and Validation of a Risk Score for Prediction of Acute Kidney Injury in Patients With Acute Decompensated Heart Failure: A Prospective Cohort Study in China. J Am Heart Assoc. Nov 16 2016;5(11). https:\/\/doi.org\/10.1161\/JAHA.116.004035.","DOI":"10.1161\/JAHA.116.004035"},{"key":"774_CR55","doi-asserted-by":"publisher","unstructured":"Rao VS et al. Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function, (in eng), Circulation. Heart failure, vol. 12, no. 6, p. e005552, 2019\/06\/\/undefined 2019, https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005552","DOI":"10.1161\/CIRCHEARTFAILURE.118.005552"},{"key":"774_CR56","doi-asserted-by":"publisher","unstructured":"Chen HH et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial, JAMA, vol. 310, no. 23, pp. 2533-43, Dec 18 2013, https:\/\/doi.org\/10.1001\/jama.2013.282190","DOI":"10.1001\/jama.2013.282190"},{"key":"774_CR57","doi-asserted-by":"publisher","unstructured":"Ahmad T et al. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury, Circulation, vol. 137, no. 19, pp. 2016\u20132028, May 8 2018. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030112","DOI":"10.1161\/CIRCULATIONAHA.117.030112"},{"key":"774_CR58","doi-asserted-by":"publisher","unstructured":"Shrestha K, Shao Z, Singh D, Dupont M, Tang WH. Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol. Nov 1 2012;110(9):1329\u201335. https:\/\/doi.org\/10.1016\/j.amjcard.2012.06.035.","DOI":"10.1016\/j.amjcard.2012.06.035"},{"key":"774_CR59","doi-asserted-by":"publisher","unstructured":"Soyler C, Tanriover MD, Ascioglu S, Aksu NM, Arici M. Urine neutrophil gelatinase-associated lipocalin levels predict acute kidney injury in acute decompensated heart failure patients. Ren Fail. Jun 2015;37(5):772\u20136. https:\/\/doi.org\/10.3109\/0886022X.2015.1033324.","DOI":"10.3109\/0886022X.2015.1033324"},{"key":"774_CR60","doi-asserted-by":"crossref","unstructured":"Nakada Y, et al. Prognostic Value of Urinary Neutrophil Gelatinase-Associated Lipocalin on the First Day of Admission for Adverse Events in Patients With Acute Decompensated Heart Failure, (in eng). J Am Heart Assoc. 2017;6(5). 2017\/05\/18\/.","DOI":"10.1161\/JAHA.116.004582"},{"key":"774_CR61","doi-asserted-by":"publisher","unstructured":"Wettersten N et al. Urine Tubular Biomarkers Are Associated With Natriuresis in Patients With Acute Heart Failure, J Am Heart Assoc, vol. 14, no. 24, p. e044812, Dec 16 2025, https:\/\/doi.org\/10.1161\/JAHA.125.044812","DOI":"10.1161\/JAHA.125.044812"},{"key":"774_CR62","doi-asserted-by":"publisher","unstructured":"Horiuchi Y, et al. Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure. ESC Heart Fail. Mar 3 2026;13(2). https:\/\/doi.org\/10.1093\/eschf\/xvag079.","DOI":"10.1093\/eschf\/xvag079"},{"key":"774_CR63","unstructured":"Bonventre JV. Kidney injury molecule-1: a translational journey, Trans Am Clin Climatol Assoc, vol. 125, pp. 293-9; discussion 299, 2014. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25125746"},{"key":"774_CR64","doi-asserted-by":"publisher","unstructured":"Henry A et al. Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization, Circulation, vol. 145, no. 16, pp. 1205\u20131217, Apr 19 2022. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056663","DOI":"10.1161\/CIRCULATIONAHA.121.056663"},{"issue":"10","key":"774_CR65","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/eurjhf\/hfr102","volume":"13","author":"CG Jungbauer","year":"2011","unstructured":"Jungbauer CG, et al. Kidney injury molecule-1 and N-acetyl-\u03b2-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome, (in eng). Eur J Heart Fail. 2011;13(10):1104\u201310. 2011\/10\/\/undefined.","journal-title":"Eur J Heart Fail"},{"key":"774_CR66","doi-asserted-by":"publisher","unstructured":"Duff S, et al. Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury. Circ Heart Fail. Nov 2024;17(11):e011751. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.011751.","DOI":"10.1161\/CIRCHEARTFAILURE.123.011751"},{"key":"774_CR67","doi-asserted-by":"crossref","unstructured":"Damman K et al. Tubular damage and worsening renal function in chronic heart failure, (in eng), JACC. Heart failure, vol. 1, no. 5, pp. 417\u2013424. 2013\/10\/\/undefined 2013, doi: 10.1016\/j.jchf.2013.05.007.","DOI":"10.1016\/j.jchf.2013.05.007"},{"key":"774_CR68","doi-asserted-by":"crossref","unstructured":"Damman K et al. Clinical outcome of renal tubular damage in chronic heart failure, (in eng), European heart journal, vol. 32, no. 21, pp. 2705\u20132712. 2011\/11\/\/undefined 2011, doi: 10.1093\/eurheartj\/ehr190.","DOI":"10.1093\/eurheartj\/ehr190"},{"issue":"6","key":"774_CR69","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/clc.23359","volume":"43","author":"M Brankovic","year":"2020","unstructured":"Brankovic M, et al. Renal tubular damage and worsening renal function in chronic heart failure: Clinical determinants and relation to prognosis (Bio-SHiFT study), (in eng). Clin Cardiol. 2020;43(6):630\u20138. 2020\/06\/\/undefined.","journal-title":"Clin Cardiol"},{"key":"774_CR70","doi-asserted-by":"publisher","unstructured":"Wettersten N et al. Kidney Tubular Biomarkers Predict Risk of Death and Heart Failure Readmission in Acute Heart Failure, J Am Heart Assoc, vol. 14, no. 18, p. e042880, Sep 16 2025, https:\/\/doi.org\/10.1161\/JAHA.125.042880","DOI":"10.1161\/JAHA.125.042880"},{"key":"774_CR71","doi-asserted-by":"publisher","unstructured":"Josa-Laorden C, et al. Elevated urinary kidney injury molecule 1 at discharge strongly predicts early mortality following an episode of acute decompensated heart failure. Pol Arch Intern Med. Sep 26 2022;132(9). https:\/\/doi.org\/10.20452\/pamw.16284.","DOI":"10.20452\/pamw.16284"},{"key":"774_CR72","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.jacc.2010.10.065","volume":"57","author":"K Damman","year":"2011","unstructured":"Damman K, et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function, (in eng). J Am Coll Cardiol. 2011;57:2233\u201341. 2011\/05\/31\/.","journal-title":"J Am Coll Cardiol"},{"key":"774_CR73","doi-asserted-by":"publisher","unstructured":"Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. Aug 2018;20(8):1988\u201393. https:\/\/doi.org\/10.1111\/dom.13301.","DOI":"10.1111\/dom.13301"},{"issue":"3","key":"774_CR74","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/ckj\/sfy122","volume":"12","author":"B Satirapoj","year":"2019","unstructured":"Satirapoj B, Korkiatpitak P, Supasyndh O. Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial. Clin Kidney J. 2019;12(3):326\u201332. https:\/\/doi.org\/10.1093\/ckj\/sfy122.","journal-title":"Clin Kidney J"},{"key":"774_CR75","doi-asserted-by":"publisher","unstructured":"Cho J, et al. Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level. Clin Pharmacol Ther. Jun 2024;115:1441\u20139. https:\/\/doi.org\/10.1002\/cpt.3237.","DOI":"10.1002\/cpt.3237"},{"key":"774_CR76","doi-asserted-by":"publisher","unstructured":"Sen T, et al. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial. Diabetes Obes Metab. Oct 2022;24(10):1950\u20136. https:\/\/doi.org\/10.1111\/dom.14779.","DOI":"10.1111\/dom.14779"},{"key":"774_CR77","doi-asserted-by":"publisher","unstructured":"Wang X, et al. IGFBP7 regulates sepsis-induced acute kidney injury through ERK1\/2 signaling. J Cell Biochem. May 2019;120(5):7602\u201311. https:\/\/doi.org\/10.1002\/jcb.28035.","DOI":"10.1002\/jcb.28035"},{"key":"774_CR78","doi-asserted-by":"publisher","unstructured":"Xu D, et al. TIMP2 promotes AKI-CKD transition by inducing tubular maladaptive repair and cell senescence via targeting Wnt\/beta-catenin signalling. Clin Transl Med. Feb 2026;16(2):e70605. https:\/\/doi.org\/10.1002\/ctm2.70605.","DOI":"10.1002\/ctm2.70605"},{"issue":"1","key":"774_CR79","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/cc12503","volume":"17","author":"K Kashani","year":"2013","unstructured":"Kashani K, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25. https:\/\/doi.org\/10.1186\/cc12503.","journal-title":"Crit Care"},{"key":"774_CR80","doi-asserted-by":"publisher","unstructured":"Ko T, et al. Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF-beta-IGFBP7 axis. Nat Commun. Jun 7 2022;13(1):3275. https:\/\/doi.org\/10.1038\/s41467-022-30630-y.","DOI":"10.1038\/s41467-022-30630-y"},{"key":"774_CR81","doi-asserted-by":"publisher","unstructured":"Kandalam V et al. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress, Circulation, vol. 124, no. 19, pp. 2094\u2009\u2013\u2009105, Nov 8 2011, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.030338","DOI":"10.1161\/CIRCULATIONAHA.111.030338"},{"issue":"2","key":"774_CR82","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/cvr\/cvu072","volume":"103","author":"D Fan","year":"2014","unstructured":"Fan D, et al. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovasc Res. 2014;103(2):268\u201380. https:\/\/doi.org\/10.1093\/cvr\/cvu072.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"774_CR83","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000538774","volume":"14","author":"G Nunez-Marin","year":"2024","unstructured":"Nunez-Marin G, et al. Urinary cell cycle arrest biomarkers and diuretic efficiency in acute heart failure. Cardiorenal Med. 2024;14(1):261\u20139. https:\/\/doi.org\/10.1159\/000538774.","journal-title":"Cardiorenal Med"},{"key":"774_CR84","doi-asserted-by":"publisher","unstructured":"Atici A, et al. Type I cardiorenal syndrome in patients with acutely decompensated heart failure: the importance of new renal biomarkers. Eur Rev Med Pharmacol Sci. Jun 2018;22(11):3534\u201343. https:\/\/doi.org\/10.26355\/eurrev_201806_15180.","DOI":"10.26355\/eurrev_201806_15180"},{"key":"774_CR85","doi-asserted-by":"publisher","unstructured":"Schanz M, Shi J, Wasser C, Alscher MD, Kimmel M. Urinary [TIMP-2] x [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. Clin Cardiol. Jul 2017;40(7):485\u201391. https:\/\/doi.org\/10.1002\/clc.22683.","DOI":"10.1002\/clc.22683"},{"key":"774_CR86","doi-asserted-by":"publisher","unstructured":"Gojaseni P, Wattanakul J, Chuasuwan A, Chittinandana A. SGLT2 inhibitor dapagliflozin reduces proximal tubular cell damage biomarkers in patients with acute heart failure. Ren Fail. Dec 2024;46(2):2373275. https:\/\/doi.org\/10.1080\/0886022X.2024.2373275.","DOI":"10.1080\/0886022X.2024.2373275"},{"key":"774_CR87","doi-asserted-by":"publisher","unstructured":"Thiele K, et al. Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. ESC Heart Fail. Aug 2022;9(4):2233\u20138. https:\/\/doi.org\/10.1002\/ehf2.13955.","DOI":"10.1002\/ehf2.13955"},{"key":"774_CR88","doi-asserted-by":"publisher","unstructured":"Ferreira JP, et al. Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme. Eur J Heart Fail. Apr 2024;26(4):806\u201316. https:\/\/doi.org\/10.1002\/ejhf.3227.","DOI":"10.1002\/ejhf.3227"},{"key":"774_CR89","doi-asserted-by":"publisher","unstructured":"Chen C, et al. Urinary Biomarkers at the Time of AKI Diagnosis as Predictors of Progression of AKI among Patients with Acute Cardiorenal Syndrome. Clin J Am Soc Nephrol. Sep 7 2016;11(9):1536\u201344. https:\/\/doi.org\/10.2215\/CJN.00910116.","DOI":"10.2215\/CJN.00910116"},{"key":"774_CR90","doi-asserted-by":"publisher","unstructured":"Barua S, et al. Acute kidney injury recovery status predicts mortality and cardiorenal outcomes in patients admitted with acute decompensated heart failure. Open Heart. Jan 4 2025;12(1). https:\/\/doi.org\/10.1136\/openhrt-2024-002928.","DOI":"10.1136\/openhrt-2024-002928"},{"key":"774_CR91","doi-asserted-by":"publisher","unstructured":"Yang X, et al. Urinary Angiotensinogen Level Predicts AKI in Acute Decompensated Heart Failure: A Prospective, Two-Stage Study. J Am Soc Nephrol. Aug 2015;26(8):2032\u201341. https:\/\/doi.org\/10.1681\/ASN.2014040408.","DOI":"10.1681\/ASN.2014040408"},{"key":"774_CR92","doi-asserted-by":"publisher","unstructured":"Amatruda JG, et al. Renin-Angiotensin-Aldosterone System Activation and Diuretic Response in Ambulatory Patients With Heart Failure. Kidney Med. Jun 2022;4(6):100465. https:\/\/doi.org\/10.1016\/j.xkme.2022.100465.","DOI":"10.1016\/j.xkme.2022.100465"},{"key":"774_CR93","doi-asserted-by":"publisher","unstructured":"Legrand M et al. Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study, (in eng), PLoS One, vol. 9, no. 11, p. e112313, 2014 2014, https:\/\/doi.org\/10.1371\/journal.pone.0112313","DOI":"10.1371\/journal.pone.0112313"},{"key":"774_CR94","doi-asserted-by":"publisher","unstructured":"Jungbauer CG et al. N-acteyl-\u00df-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure, (in eng), Nephrology (Carlton), vol. 21, no. 6, pp. 490\u2013498, 2016\/06\/\/undefined 2016. https:\/\/doi.org\/10.1111\/nep.12632","DOI":"10.1111\/nep.12632"},{"key":"774_CR95","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/bmm-2020-0366","volume":"15","author":"C Strack","year":"2021","unstructured":"Strack C, et al. N-acetyl-\u00df-D-glucosaminidase is predictive of mortality in chronic heart failure: a 10-year follow-up, (in eng). Biomark Med. 2021;15:1143\u201353. https:\/\/doi.org\/10.2217\/bmm-2020-0366. 2021\/09\/\/undefined.","journal-title":"Biomark Med"},{"key":"774_CR96","doi-asserted-by":"publisher","unstructured":"Funabashi S, et al. Elevated admission urinary N-acetyl-beta-D-glucosamidase level is associated with worse long-term clinical outcomes in patients with acute heart failure. Eur Heart J Acute Cardiovasc Care. Aug 2020;9(5):429\u201336. https:\/\/doi.org\/10.1177\/2048872620901986.","DOI":"10.1177\/2048872620901986"},{"key":"774_CR97","doi-asserted-by":"publisher","unstructured":"Zhao T, et al. Prognostic Value of Urinary N-Acetyl-beta-d-Glucosaminidase as a Marker of Tubular Damage in Patients with Heart Failure and Mitral Regurgitation. Rev Cardiovasc Med. Aug 2023;24(8):219. https:\/\/doi.org\/10.31083\/j.rcm2408219.","DOI":"10.31083\/j.rcm2408219"},{"key":"774_CR98","doi-asserted-by":"publisher","unstructured":"Imiela T, et al. The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization. ESC Heart Fail. Dec 2025;12(6):4486\u201394. https:\/\/doi.org\/10.1002\/ehf2.70004.","DOI":"10.1002\/ehf2.70004"},{"key":"774_CR99","doi-asserted-by":"publisher","unstructured":"Rangaswami J et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association, (in eng), Circulation, vol. 139, no. 16, pp. e840-e878, 2019\/04\/16\/ 2019, https:\/\/doi.org\/10.1161\/CIR.0000000000000664","DOI":"10.1161\/CIR.0000000000000664"},{"key":"774_CR100","doi-asserted-by":"publisher","unstructured":"Nishiyama A, Kobori H. Independent regulation of renin-angiotensin-aldosterone system in the kidney. Clin Exp Nephrol. Dec 2018;22(6):1231\u20139. https:\/\/doi.org\/10.1007\/s10157-018-1567-1.","DOI":"10.1007\/s10157-018-1567-1"},{"key":"774_CR101","doi-asserted-by":"publisher","unstructured":"Kishimoto T, Maekawa M, Abe Y, Yamamoto K. Intrarenal distribution of blood flow and renin release during renal venous pressure elevation, Kidney Int, vol. 4, no. 4, pp. 259\u2009\u2013\u200966, Oct 1973, https:\/\/doi.org\/10.1038\/ki.1973.112","DOI":"10.1038\/ki.1973.112"},{"issue":"22","key":"774_CR102","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2169\/internalmedicine.5212-20","volume":"59","author":"S Yokoyama","year":"2020","unstructured":"Yokoyama S, et al. Time course changes in urinary angiotensinogen and circulating N-terminal pro-B-type natriuretic peptide in patients hospitalized with acute heart failure. Intern Med. 2020;59(22):2839\u201347. https:\/\/doi.org\/10.2169\/internalmedicine.5212-20.","journal-title":"Intern Med"},{"key":"774_CR103","doi-asserted-by":"publisher","unstructured":"Ohashi N, et al. Increased heart rate is associated with intrarenal renin-angiotensin system activation in chronic kidney disease patients. Clin Exp Nephrol. Sep 2019;23(9):1109\u201318. https:\/\/doi.org\/10.1007\/s10157-019-01746-1.","DOI":"10.1007\/s10157-019-01746-1"},{"key":"774_CR104","doi-asserted-by":"publisher","unstructured":"Scholtes RA, et al. The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet. Kidney Int Rep. May 2022;7(5):1084\u201392. https:\/\/doi.org\/10.1016\/j.ekir.2022.02.023.","DOI":"10.1016\/j.ekir.2022.02.023"},{"issue":"8","key":"774_CR105","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1097\/HJH.0b013e328362217c","volume":"31","author":"F Persson","year":"2013","unstructured":"Persson F, Lu X, Rossing P, Garrelds IM, Danser AH, Parving HH. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? J Hypertens. 2013;31(8):1646\u201352. https:\/\/doi.org\/10.1097\/HJH.0b013e328362217c.","journal-title":"J Hypertens"},{"key":"774_CR106","doi-asserted-by":"publisher","unstructured":"Novak R, Salai G, Hrkac S, Vojtusek IK, Grgurevic L. Revisiting the Role of NAG across the Continuum of Kidney Disease. Bioeng (Basel). Apr 4 2023;10(4). https:\/\/doi.org\/10.3390\/bioengineering10040444.","DOI":"10.3390\/bioengineering10040444"},{"key":"774_CR107","doi-asserted-by":"publisher","unstructured":"Brankovic M, et al. Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. Kidney Int. Apr 2018;93(4):952\u201360. https:\/\/doi.org\/10.1016\/j.kint.2017.09.013.","DOI":"10.1016\/j.kint.2017.09.013"},{"key":"774_CR108","doi-asserted-by":"publisher","unstructured":"Nunoi K, Sato Y, Kaku K, Yoshida A, Suganami H. Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. Endocrinol Diabetes Metab. Apr 2018;1(2):e00015. https:\/\/doi.org\/10.1002\/edm2.15.","DOI":"10.1002\/edm2.15"},{"key":"774_CR109","doi-asserted-by":"publisher","unstructured":"Diaz-Riera E, Garcia-Arguinzonis M, Lopez L, Garcia-Moll X, Badimon L, Padro T. Urinary Proteomic Signature in Acute Decompensated Heart Failure: Advances into Molecular Pathophysiology. Int J Mol Sci. Feb 20 2022;23(4). https:\/\/doi.org\/10.3390\/ijms23042344.","DOI":"10.3390\/ijms23042344"},{"key":"774_CR110","doi-asserted-by":"publisher","unstructured":"Carland C et al. Urinary Proteomics and Outcomes in Heart Failure With Preserved Ejection Fraction, J Am Heart Assoc, vol. 13, no. 9, p. e033410, May 7 2024, https:\/\/doi.org\/10.1161\/JAHA.123.033410","DOI":"10.1161\/JAHA.123.033410"},{"key":"774_CR111","doi-asserted-by":"publisher","unstructured":"Wu A et al. Identification of Biomarkers for Right Ventricular Dysfunction in Idiopathic Dilated Cardiomyopathy Via Urinary Proteomics and Machine Learning, J Am Heart Assoc, vol. 15, no. 1, p. e044254, Jan 6 2026, https:\/\/doi.org\/10.1161\/JAHA.125.044254","DOI":"10.1161\/JAHA.125.044254"},{"key":"774_CR112","doi-asserted-by":"publisher","unstructured":"Kuznetsova T, Mischak H, Mullen W, Staessen JA. Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J. Sep 2012;33(18):2342\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehs185.","DOI":"10.1093\/eurheartj\/ehs185"},{"issue":"6","key":"774_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157167","volume":"11","author":"K Rossing","year":"2016","unstructured":"Rossing K, et al. Urinary proteomics pilot study for biomarker discovery and diagnosis in heart failure with reduced ejection fraction. PLoS One. 2016;11(6):e0157167. https:\/\/doi.org\/10.1371\/journal.pone.0157167.","journal-title":"PLoS One"},{"key":"774_CR114","doi-asserted-by":"publisher","unstructured":"He T, et al. Urinary peptides in heart failure: a link to molecular pathophysiology. Eur J Heart Fail. Nov 2021;23(11):1875\u201387. https:\/\/doi.org\/10.1002\/ejhf.2195.","DOI":"10.1002\/ejhf.2195"},{"key":"774_CR115","doi-asserted-by":"publisher","unstructured":"Collier P, et al. Getting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype. J Mol Cell Cardiol. 2012;52(1):148\u201353. https:\/\/doi.org\/10.1016\/j.yjmcc.2011.10.002.","DOI":"10.1016\/j.yjmcc.2011.10.002"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00774-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-026-00774-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00774-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:03:02Z","timestamp":1786366982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-026-00774-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1007\/s11897-026-00774-9","relation":{},"ISSN":["1546-9549"],"issn-type":[{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Roehm receives fees for scientific consulting from Revamp Medical. Dr. Grodin reports personal fees from Pfizer, Alnylam, Eidos\/BridgeBio, AstraZeneca, Alexion, Lumanity, Novo Nordisk, Ultromics, Intellia, and Tenax Therapeutics, and grant support from NHLBI (R01HL160892 and R01HL172993), Pfizer (67656485), Eidos\/BridgeBio, and Texas Health Resources Clinical Scholars Fund. Dr. Toto reports serving on Data Monitoring Committees for AstraZeneca and Alnlyam. He is also a site principal investigator for Vertex Pharma clinical trial and receives grant support from NIH.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"39"}}